Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4318MR)

This product GTTS-WQ4318MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4318MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2651MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ14054MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ10789MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ7678MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ11918MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ2464MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ7674MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ661MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW